GE HealthCare Reports Q2 Earnings Beat Driven by Imaging Demand and Tariff Refunds
GE HealthCare reported second-quarter net income of $561 million for 2026, up from $486 million in the same period a year earlier. The increase was driven by strong demand for imaging devices and pharmaceutical diagnostics, as well as refunds on tariffs imposed under former President Donald Trump. Revenue rose to $5.3 billion, with organic growth of 3.5%. Advanced Imaging Solutions and Pharmaceutical Diagnostics segments saw revenue increases of 7.9% and 15.6%, respectively. The company's adjusted earnings per share came in at $1.13, exceeding the average analyst estimate of $1.04. The results included a $129 million net income benefit from tariff refunds after court rulings deemed them unlawfully collected. However, geopolitical tensions and rising costs for memory chips, oil, and freight impacted margins. GE HealthCare reaffirmed its full-year 2026 guidance despite challenges in the Patient Care Solutions segment, which saw a revenue decline of 13.3%. The company is exploring strategic options to maximize long-term value from this division.
Tickers: $GEHC